Home > News > Starpharma gets US nod to work on HIV gel
November 19th, 2003
Starpharma gets US nod to work on HIV gel
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday. Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration. He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013